Ucello Biotechnology

Ucello Biotechnology is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, focused on the development of next-generation universal CAR-T (UCAR-T) cell therapies. The company utilizes its proprietary U-Cell platform to create "off-the-shelf" cell products designed to address the scalability and cost challenges associated with traditional autologous CAR-T treatments. Their pipeline features multi-targeted candidates, such as dual CD19/CD22 therapies, aimed at treating refractory hematologic malignancies like B-cell acute lymphoblastic leukemia. By leveraging advanced gene editing and cell expansion technologies, Ucello aims to provide safer, more accessible, and more effective immunotherapy options for patients globally.